CNTA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.391

-33.13%

-0.412

+106.25%

-0.404

+6.32%

Estimates Revision

The market is revising Upward the revenue expectations for Centessa Pharmaceuticals plc (CNTA) for FY2025, with the revenue forecasts being adjusted by 4.72% over the past three months. During the same period, the stock price has changed by 22.60%.

Revenue Estimates for FY2025

Revise Upward

+4.72%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.08%

In Past 3 Month

Stock Price

Go Up

+22.60%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 37.55 USD with a low forecast of 27.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 26.150

Low

27.00

Averages

37.55

High

52.00

Current: 26.150

Low

27.00

Averages

37.55

High

52.00

Oppenheimer

Outperform

upgrade

$40 -> $62

2025-12-10

Reason

Oppenheimer

Price Target

$40 -> $62

2025-12-10

upgrade

Outperform

Reason

Oppenheimer assumed coverage of Centessa with an Outperform rating with a price target of $62, up from $40. Centessa is a top pick for the firm. Oppenheimer notes that the company's pipeline includes best-in-class orexin agonists, with an expected commercialization in the first half of 2028 that can significantly expand the size of the current narcolepsy market via higher diagnosis/uptake/compliance/pricing compared to approved drugs. The firm thinks Centessa is significantly undervalued and expects upside potential during data readouts throughout 2026 and beyond.

Stifel

maintain

2025-11-05

Reason

Stifel

Price Target

2025-11-05

maintain

Reason

Stifel expects shares of Alkermes (ALKS) to move higher on the narcolepsy type 1 data reported by Centessa (CNTA). The initial clinical disclosure from Centessa's orexin program does not look superior to Alkermes' ALKS2680, the analyst tells investors in a research note. Stifel says Alkermes shares were pricing in some fear that Centessa could have a much superior profile. The firm believes orexins could be a "significant blockbuster class" with room for many players. It keeps a Buy rating on Alkermes. The stock in morning trading is up 10%, or $2.90, to $33.29.

Stephens

Loganathan

Overweight

initiated

$35

2025-10-28

Reason

Stephens

Loganathan

Price Target

$35

2025-10-28

initiated

Overweight

Reason

Stephens analyst Sudan Loganathan initiated coverage of Centessa with an Overweight rating and $35 price target. The company's lead asset ORX750 has demonstrated "significant" and dose-dependent improvements in mean sleep latency on the Maintenance of Wakefulness Test, the analyst tells investors in a research note. The firm believes the orexin agonist could have therapeutic benefits to narcolepsy and idiopathic hypersomnia patients.

LifeSci Capital

NULL -> Outperform

initiated

$37

2025-09-03

Reason

LifeSci Capital

Price Target

$37

2025-09-03

initiated

NULL -> Outperform

Reason

LifeSci Capital initiated coverage of Centessa with an Outperform rating and $37 price target.

Wells Fargo

Overweight

initiated

$31

2025-09-02

Reason

Wells Fargo

Price Target

$31

2025-09-02

initiated

Overweight

Reason

Wells Fargo initiated coverage of Centessa with an Overweight rating and $31 price target. Near-term OX2R, orexin-2 receptor, agonism data in narcolepsy type-1,2, and idiopathic hypersomnia, or IH, offer meaningful catalysts for Centessa, the analyst tells investors in a research note. The company's NT2/IH data expected this year should have a greater capacity to re-rate shares, the firm added.

Oppenheimer

Outperform

initiated

$40

2025-08-29

Reason

Oppenheimer

Price Target

$40

2025-08-29

initiated

Outperform

Reason

Oppenheimer resumed coverage of Centessa with an Outperform rating and $40 price target. The firm cites its conviction for lead asset ORX750 to represent best-in-class potential among orexin-2 receptor agonists, with near-term Phase 2a CRYSTAL-1 data in idiopathic hypersomnia and narcolepsy type-1 and -2 expected this year - likely Q4 2025, given ct.gov information. Presentations at World Sleep for other OX2R agonists should inform the competitive bar for ORX750. Oppenheimer believes the market opportunity for ORX750 is substantial.

Valuation Metrics

The current forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA.O) is -16.14, compared to its 5-year average forward P/E of -6.14. For a more detailed relative valuation and DCF analysis to assess Centessa Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.14

Current PE

-16.14

Overvalued PE

-2.38

Undervalued PE

-9.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.54

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.46

Undervalued EV/EBITDA

-8.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

204.35

Current PS

0.00

Overvalued PS

1142.77

Undervalued PS

-734.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 325.14% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNTA News & Events

Events Timeline

No data

News

5.0

12-11Globenewswire

Centessa Pharmaceuticals Appoints Accardi as CEO, Focusing on Orexin Drug Development

5.0

12-11Newsfilter

Centessa Pharmaceuticals Appoints Accardi as CEO, Focusing on Orexin Drug Development

5.0

12-11NASDAQ.COM

Centessa Pharmaceuticals CEO Saurabh Saha Resigns; Mario Accardi Appointed as Successor

People Also Watch

Frequently Asked Questions

What is Centessa Pharmaceuticals PLC (CNTA) stock price today?

The current price of CNTA is 26.15 USD — it has decreased -1.36 % in the last trading day.

What is Centessa Pharmaceuticals PLC (CNTA)'s business?

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

What is the price predicton of CNTA Stock?

What is Centessa Pharmaceuticals PLC (CNTA)'s revenue for the last quarter?

Centessa Pharmaceuticals PLC revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Centessa Pharmaceuticals PLC (CNTA)'s earnings per share (EPS) for the last quarter?

Centessa Pharmaceuticals PLC. EPS for the last quarter amounts to -0.41 USD, increased 10.81 % YoY.

What changes have occurred in the market's expectations for Centessa Pharmaceuticals PLC (CNTA)'s fundamentals?

How many employees does Centessa Pharmaceuticals PLC (CNTA). have?

Centessa Pharmaceuticals PLC (CNTA) has 77 emplpoyees as of December 16 2025.

What is Centessa Pharmaceuticals PLC (CNTA) market cap?

Today CNTA has the market capitalization of 3.82B USD.